Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 560 • 2015 ACR/ARHP Annual Meeting
Impact of Anti-Citrullinated Protein Antibody Status and Response to Abatacept
Leslie Harrold^1,2, KK Gandhi³, H Litman⁴, S Kelly³, YF Li⁵, E Alemao³, S Deveikis⁴ and J Greenberg^1,6, ¹Corrona, LLC, Southborough, MA, ²Dept of Medicine, University of Massachusetts Medical School, Worcester, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC., Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶NYU School of Medicine, New York, NY
Background/Purpose: Response to therapies may vary based on anti-citrullinated protein antibodies (ACPA) status. We compared treatment response to abatacept in ACPA-positive versus -negative RA patients…
Abstract Number: 2768 • 2015 ACR/ARHP Annual Meeting
Trend and Factors Associated with Switching Treatment after Initial Anti-TNF Therapy Among Patients with Rheumatoid Arthritis
Wenhui Wei¹, Emma Sullivan², Chieh-I Chen³, James Piercy² and Stuart Blackburn², ¹Sanofi-Aventis, Bridgewater, NJ, ²Adelphi Real World, Manchester, United Kingdom, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Among rheumatoid arthritis (RA) patients who progress beyond their first biologic disease-modifying antirheumatic drug (bDMARD), in-class cycling between different tumor necrosis factor inhibitors (TNFi)…
Abstract Number: 574 • 2015 ACR/ARHP Annual Meeting
Metabolomic Profiling Predicts Outcome of Rituximab Therapy in Rheumatoid Arthritis
Shannon Sweeney¹, Arthur Kavanaugh², Alessia Lodi³, Bo Wang¹, David L. Boyle⁴, Stefano Tiziani⁵ and Monica Guma⁶, ¹University of Texas at Austin, Austin, TX, ²University of California San Diego, La Jolla, CA, ³nutritional Sciences, University of Texas at Austin, Austin, TX, ⁴Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ⁵Nutritional Sciences, University of Texas at Austin, Austin, TX, ⁶Pharmacology, University of California, San Diego, La Jolla, CA
Background/Purpose: We hypothesized that characterization of patients’ metabolic profiles, utilizing both high-resolution 1H-nuclear magnetic resonance (NMR) and mass spectrometry (MS), might help predict response to…
Abstract Number: 2769 • 2015 ACR/ARHP Annual Meeting
Factors Associated with TNF Switching: a Retrospective Real-World Study of Patients with Rheumatoid Arthritis
Wenhui Wei¹, Keith Knapp², Li Wang³, Chieh-I Chen⁴, Gary Craig², Karen Ferguson² and Sergio Schwartzman⁵, ¹Sanofi-Aventis, Bridgewater, NJ, ²Discus Analytics, Inc., Spokane, WA, ³Director, Analytic Research, STATinMED Research, Plano, TX, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Switching of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patient treatment is common in real-world clinical practice. The context for why patients switch…
Abstract Number: 1485 • 2014 ACR/ARHP Annual Meeting
Analysis of Patient-Reported Outcomes during Treatment with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá, in the Randomized Phase 2b Earth Explorer 1 Study
Joel M. Kremer¹, Gerd Burmester², Michael Weinblatt³, Angela Williams⁴, Niklas Karlsson⁵, Alex Godwood⁶ and David Close⁷, ¹Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ²Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ³Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁴MedImmune Ltd, Cambridge, United Kingdom, ⁵Health Economics and Outcomes Research, AstraZeneca, Molndal, Sweden, ⁶Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, ⁷Clinical Development, MedImmune Ltd, Cambridge, United Kingdom
Background/Purpose Active RA significantly impairs health-related quality of life (HRQoL) and physical function of patients. Granulocyte-macrophage colony-stimulating factor (GM-CSF) plays a key role in macrophage…
Abstract Number: 1452 • 2014 ACR/ARHP Annual Meeting
Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting
Yomei Shaw¹, Chung-Chou H. Chang², Marc C. Levesque³, Julie M. Donohue⁴, Kaleb Michaud^5,6 and Mark S. Roberts¹, ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ⁴Health Policy & Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁵National Data Bank for Rheumatic Diseases, Wichita, KS, ⁶Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Current guidelines recommend that rheumatoid arthritis (RA) patients with poor response to their current regimen of disease modifying anti-rheumatic drugs (DMARDs) have therapy adjusted…
Abstract Number: 2923 • 2014 ACR/ARHP Annual Meeting
Protein Quantification Using Mass Spectrometry Methods to Predict Response to Abatacept and Methotrexate Combination Therapy in Rheumatoid Arthritis
A Obry^1,2, P Cosette², T Lequerré^1,3, Maria-Antonietta d'Agostino⁴, C Gaillez⁵, M Le Bars⁶ and O Vittecoq^1,3, ¹Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²UMR 6270 CNRS, PISSARO Proteomic Facility, IRIB, Normandy University, University of Rouen, Rouen, France, ³Department of Rheumatology, Rouen University Hospital, Rouen, France, ⁴AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ⁵Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, ⁶Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: Targeted biologic therapies with different mechanisms of action are commonly used in RA. Abatacept is a recombinant fusion protein that inhibits T-cell co-stimulatory molecules…
Abstract Number: 1407 • 2014 ACR/ARHP Annual Meeting
Low HAQ and Pain Predict Patient Perceived Remission in Rheumatoid Arthritis Patients Receiving MTX or Anti-TNF-Alpha Treatment
Paul Studenic¹, Josef Smolen² and Daniel Aletaha¹, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine 3, Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose The induction of remission is the primary target of RA therapy. Failing to achieve the patient global estimate of disease activity criterion (PGA
Abstract Number: 2912 • 2014 ACR/ARHP Annual Meeting
Impact of Failure to Adhere to Treat-to-Target of Rheumatoid Arthritis in Real World Practice: Data from the International Rheumatoid Arthritis Biomarker Program
Walter P. Maksymowych^1,2, M. Østergaard³, O Elkayam⁴, R Landewé⁵, J Homik⁶, C Thorne⁷, M Backhaus⁸, S Shaikh⁹, G Boire¹⁰, M Larche¹¹, B Combe¹², T Schaeverbeke¹³, A Saraux¹⁴, G Ferraccioli¹⁵, M Dougados¹⁶, C Barnabe¹⁷, M Govoni¹⁸, PP Tak¹⁹, D. van Schaardenburg²⁰, D van der Heijde²¹, R Dadashova², E Hutchings², J Paschke² and Oliver FitzGerald²², ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²CaRE Arthritis, Edmonton, AB, Canada, ³Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁴Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁵Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ⁹Niagara Peninsula Arthritis Centre, Hamilton, ON, Canada, ¹⁰CHUS-Sherbrooke University, Sherbrooke, QC, Canada, ¹¹St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ¹²Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ¹³Bordeaux University Hospital, Bordeaux, France, ¹⁴CHU Brest and EA 2216, UBO, Brest, France, ¹⁵Catholic University of The Sacred Heart, Rome, Italy, ¹⁶Hopital Cochin, Paris, France, ¹⁷University of Calgary, Calgary, AB, Canada, ¹⁸Universita di Ferrara, Ferrara, Italy, ¹⁹Academic Medical Center, Amsterdam, Netherlands, ²⁰Jan van Breemen Research Institute, Amsterdam, Netherlands, ²¹Leiden University Medical Center, Leiden, Netherlands, ²²St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose . There is limited data on adherence to treat-to-target (T2T) strategies in RA in real world-practice and the impact of failure to adopt this…
Abstract Number: 1384 • 2014 ACR/ARHP Annual Meeting
Fibromyalgia and Its Effect on Treatment Response in Early Rheumatoid Arthritis Patients
Josefina Durán Santa Cruz¹, Bernard Combe², Jingbo Niu¹, Nathalie Rincheval³, Cécile Gaujoux-Viala⁴ and David T. Felson⁵, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ³Institut Universitaire de Recherche Clinique, Montpellier, France, ⁴EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, ⁵Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Fibromyalgia (FM) occurs commonly in patients with rheumatoid arthritis (RA) and its effect on treatment response is unknown. In this study we aimed to…
Abstract Number: 2517 • 2014 ACR/ARHP Annual Meeting
Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders
Josef Smolen¹, Ronald F. van Vollenhoven², Stefan Florentinus³, Yijie Zhou⁴, Benoit Guerette⁴ and Arthur Kavanaugh⁵, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³AbbVie, Rungis, France, ⁴AbbVie, Inc., North Chicago, IL, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Methotrexate (MTX) is used as first line therapy for treatment of rheumatoid arthritis (RA). Current recommendations state that therapy should be adjusted if patients…
Abstract Number: 946 • 2014 ACR/ARHP Annual Meeting
Phase 1 Study of Immunotherapy Using Autoantigen-Loaded Dendritic Cells in Patients with Anti-Citrullinated Peptide Antigen Positive Rheumatoid Arthritis
Young Bin Joo¹, Jun-Eui Park², Chan-Bum Choi³, Jeongim Choi¹, Jin-ah Jang², Minkyu Heo², Hak-yeop Kim², Hye-Soon Lee⁴, Yong-Soo Bae⁵ and Sang-Cheol Bae¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²JW CreaGene Research Institute, JWCreaGene Inc., Seongnam-si, South Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁵3Department of Biological Science, Sungkyunkwan University, Suwon, South Korea
Background/Purpose To date, no dendritic cell (DC) immunotherapy has been shown to give a benefit in patients with rheumatoid arthritis (RA). In this prospective phase…
Abstract Number: 2498 • 2014 ACR/ARHP Annual Meeting
Characteristics of Responding Versus Non-Responding Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate
Josef Smolen¹, David Collier², Annette Szumski³, Heather Jones⁴ and Lisa Marshall⁵, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Amgen, Inc., Thousand Oaks, CA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ⁵Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose While synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) are often effective, treatment with such agents does not adequately control disease activity in all patients.…
Abstract Number: 398 • 2014 ACR/ARHP Annual Meeting
Anti-Rheumatic Therapy Decreases Syndecan-1 Shedding in Rheumatoid Arthritis (RA)
Ivana Hollan¹, Gunnbjørg Hjeltnes², Torstein Lyberg³, Stefan Agewall³, Allan Wiik⁴, Knut Mikkelsen⁵, Øystein T. Førre⁶, Tram T. Vuong³ and Svein O. Kolset³, ¹Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ²Medicine, Innlandet Hospital Trust, Lillehammer, Norway, ³University of Oslo, Oslo, Norway, ⁴Clinical Biochem/Immunology, Statens Serum Institute, Copenhagen S, Denmark, ⁵Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁶Oslo University Hospital, Oslo, Norway
Background/Purpose Intact glycocalyx is of importance for healthy endothelial function. Changes in the endothelial glycocalyx, characterized by increased levels of circulating syndecan-1, might be related…
Abstract Number: 2492 • 2014 ACR/ARHP Annual Meeting
Does Body Mass Index Impact Long-Term Retention with Abatacept in Patients with RA Who Have Received at Least One Prior Biologic Agent? 2-Year Results from a Real-World, International, Prospective Study
H Nüßlein¹, R Alten², M Galeazzi³, HM Lorenz⁴, MT Nurmohamed⁵, WG Bensen⁶, Gerd Burmester⁷, H-H Peter⁸, P Peichl⁹, K Pavelka¹⁰, M Chartier¹¹, C Poncet¹², C Rauch¹³ and M Le Bars¹⁴, ¹Internistische Schwerpunktpraxis, Nürnberg, Germany, ²Schlosspark-Klinik University Medicine, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital, Heidelberg, Germany, ⁵VU Univ Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Charité-Universitätsmedizin, Berlin, Germany, ⁸University of Freiburg, Freiburg, Germany, ⁹Evangelisches Krankenhaus, Vienna, Austria, ¹⁰Institute of Rheumatology, Charles University, Prague, Czech Republic, ¹¹Chiltern International, Neuilly, France, ¹²Docs International, Nanterre, France, ¹³Bristol-Myers Squibb, Munich, Germany, ¹⁴Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: In RA, reduced efficacy with anti-TNF therapy1 and dose escalation2 have been reported for obese patients (pts) compared with non-obese pts. Clinical trials have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].